Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1/2 A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients
The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme. All subjects will receive NG101m capsules along with the standard treatment of temozolomide and radiation.
100 Clinical Results associated with NeuGATE Theranostics
0 Patents (Medical) associated with NeuGATE Theranostics
100 Deals associated with NeuGATE Theranostics
100 Translational Medicine associated with NeuGATE Theranostics